Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Baxter
Dow
McKesson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,213,444

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,213,444
Title:Composition and method for treating bipolar disorder
Abstract: Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combination therapy of minocycline and acetylsalicylic acid delivered in doses that improve metabolic function and/or exert immune-modulating and/or anti-inflammatory effects. Also disclosed is a method for treating individuals suffering from the indicated disorders.
Inventor(s): Drevets; Wayne Curtis (Newton, PA), Yates; William Robert (Tulsa, OK), Savitz; Jonathan Bradley (Tulsa, OK), Preskorn; Sheldon H. (Wichita, KS)
Assignee: Laureate Institute For Brain Research (Tulsa, OK)
Application Number:15/532,851
Patent Claims:1. A method for treating bipolar depression in an individual comprising: delivering, as a single drug delivery system, to an individual with bipolar depression a pharmacologically effective amount of a compound capable of inhibiting a COX-1enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain.

2. The method of claim 1, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme.

3. The method of claim 1, wherein said single drug delivery system delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1 enzyme to said individual.

4. The method of claim 1, wherein said method delivers said compound capable of inhibiting a COX-1 enzyme and said compound capable of modulating the release of cytokines from microglial cells in the brain to said individual twice a day.

5. The method of claim 1, wherein said method delivers said compound capable of inhibiting a COX-1 enzyme and said compound capable of modulating the release of cytokines from microglial cells in the brain to said individual once in the morning and once in the evening.

6. The method of claim 1 wherein said compound capable of inhibiting a COX-1 enzyme is selected from the group consisting of: acetylsalicylic acid and naproxen.

7. The method of claim 1, wherein said compound capable of modulating the release of cytokines from microglial cells in the brain is selected from the group consisting of minocycline, adalimumab, certolizumab, pegol, anakinra, rilonacept and canakinumab.

8. A method for treating bipolar depression in an individual comprising: delivering, as a single drug delivery system, to an individual with bipolar depression and a body mass index of greater than 25 a pharmacologically effective amount of a compound capable of inhibiting a COX-1 enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain.

9. The method of claim 8, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme.

10. The method of claim 8, wherein said single drug delivery system delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1 enzyme.

11. A method for treating bipolar depression in a female individual comprising: delivering, as a single drug delivery system, to a female individual with bipolar depression a pharmacologically effective amount of a compound capable of inhibiting a COX-1 enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain.

12. The method of claim 11, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme.

13. The method of claim 11, wherein said pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight to said individual.

Summary for Patent:   Start Trial

PCT Information
PCT FiledDecember 04, 2015PCT Application Number:PCT/US2015/064106
PCT Publication Date:June 09, 2016PCT Publication Number:WO2016/090316

Details for Patent 10,213,444

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Laureate Institute For Brain Research (Tulsa, OK) 2034-12-04 RX Orphan search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   Start Trial Laureate Institute For Brain Research (Tulsa, OK) 2034-12-04 RX Orphan search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   Start Trial Laureate Institute For Brain Research (Tulsa, OK) 2034-12-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
Harvard Business School
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.